The global antipsychotic drugs market is
expected to reach USD 14.4 billion by 2025, according to a new report by Grand
View Research, Inc. The continuous development of better next-generation
products to overcome adverse effects and unwanted reactions of existing
products is creating demand for newer products. This factor is anticipated to
propel the market.
Rapid growth of antipsychotics
can be attributed to the rising prevalence of psychosis and other mental
disorders. Governments are focused on creating awareness regarding mental
health and psychological illnesses, which is further anticipated to drive the
demand for antipsychotics. Government bodies in collaboration with major
players conduct social programs to break the stigma related to psychotic
disorders that exists in the society.
Adverse effects of
antipsychotics, such as insomnia, dry mouth, drowsiness, and blurred vision,
are expected to affect the growth by decreasing the level of acceptance in
patients. In addition, the possibility of dependency, habit formation, or
addiction is affecting the adoption of these drugs.
Established brands such as,
Zyprexa lost patent protection in October 2011, followed by Seroquel and
Risperdal in 2012, which hampers the market growth for these drugs. Also, the
entry of generic versions of these products slowed the growth of the already
existing brands.
Browse full research report on Global Antipsychotic Drugs Market: http://www.grandviewresearch.com/industry-analysis/antipsychotic-drugs-market
Further Key Findings From
the Study Suggest:
- The growing prevalence of mental disorders, increased investments on R&D, and rising awareness regarding these conditions are augmenting the growth of the market.
- The first-generation of antipsychotics have serious adverse effects and are very rarely used, hence they hold negligible share in the market.
- The second-generation segment of drugs accounted for the largest share in 2015 and are anticipated to further expand during the forecast period despite the adverse effects
- As of January 2016, the third-generation segment has only one approved product, Abilify. It has negligible adverse effects and is expected to be the fastest growing segment over the forecast period
- In 2015, North America dominated the global space with the largest revenue share owing to rising prevalence of mental illnesses
- Asia Pacific is expected to emerge as the fastest growing region during the forecast period, mainly due to growing social awareness regarding mental disorders and improving access to treatment
- Some of the major players in this market are Johnson & Johnson; Pfizer, Inc.; Eli Lilly & Co.; and Bristol-Myers Squibb
Grand View Research has segmented the antipsychotic drugs
market by drug class, application, and region:
Antipsychotics Drug Class Outlook (Revenue, USD Million;
2014 - 2025)
- First Generation
- Second Generation
- Third Generation
Antipsychotics Application Outlook (Revenue, USD Million;
2014 - 2025)
- Schizophrenia
- Bipolar disorder
- Unipolar depression
- Dementia
- Others
Antipsychotics Regional Outlook (Revenue, USD Million;
2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- Japan
- Latin America
- Mexico
- Brazil
- MEA
- South Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment